Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human FLT4 Antibodies:
anti-Mouse (Murine) FLT4 Antibodies:
anti-Rat (Rattus) FLT4 Antibodies:
Go to our pre-filtered search.
Mouse (Murine) Polyclonal FLT4 Primary Antibody for CyTOF, FACS - ABIN4899930
Benedito, Rocha, Woeste, Zamykal, Radtke, Casanovas, Duarte, Pytowski, Adams: Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. in Nature 2012
Show all 25 Pubmed References
Human Monoclonal FLT4 Primary Antibody for FACS - ABIN4896918
Roorda, Ter Elst, Scherpen, Meeuwsen-de Boer, Kamps, de Bont: VEGF-A promotes lymphoma tumour growth by activation of STAT proteins and inhibition of p27(KIP1) via paracrine mechanisms. in European journal of cancer (Oxford, England : 1990) 2010
Show all 5 Pubmed References
Human Monoclonal FLT4 Primary Antibody for FACS - ABIN4896919
Shawber, Funahashi, Francisco, Vorontchikhina, Kitamura, Stowell, Borisenko, Feirt, Podgrabinska, Shiraishi, Chawengsaksophak, Rossant, Accili, Skobe, Kitajewski: Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. in The Journal of clinical investigation 2007
Show all 5 Pubmed References
Human Monoclonal FLT4 Primary Antibody for ELISA (Detection), FACS - ABIN4899932
Mouawad, Spano, Comperat, Capron, Khayat: Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. in European journal of cancer (Oxford, England : 1990) 2009
Show all 4 Pubmed References
Human Monoclonal FLT4 Primary Antibody for WB - ABIN1882290
Pajusola, Aprelikova, Korhonen, Kaipainen, Pertovaara, Alitalo, Alitalo: FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. in Cancer research 1992
Show all 4 Pubmed References
Human Monoclonal FLT4 Primary Antibody for ELISA, WB - ABIN969147
Goodyear, Kheyfets, Garcia, Stearns: Role of the VEGFR3/VEGFD receptor axis in TGFbeta1 activation of primary prostate cell lines. in The Prostate 2009
Show all 3 Pubmed References
Human Polyclonal FLT4 Primary Antibody for FACS, IF (p) - ABIN678578
Wang, Zhou, Lin, Wang, Lin, Li: RhGH attenuates ischemia injury of intrahepatic bile ducts relating to liver transplantation. in The Journal of surgical research 2011
Show all 3 Pubmed References
Mouse (Murine) Monoclonal FLT4 Primary Antibody for IHC (fro), IHC (p) - ABIN967368
Kubo, Fujiwara, Jussila, Hashi, Ogawa, Shimizu, Awane, Sakai, Takabayashi, Alitalo, Yamaoka, Nishikawa: Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. in Blood 2000
Show all 2 Pubmed References
Human Monoclonal FLT4 Primary Antibody for IHC, ELISA - ABIN1003451
Jussila, Valtola, Partanen, Salven, Heikkilä, Matikainen, Renkonen, Kaipainen, Detmar, Tschachler, Alitalo, Alitalo: Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. in Cancer research 1998
Mouse (Murine) Monoclonal FLT4 Primary Antibody for WB - ABIN1589862
Tempfer, Kaser-Eichberger, Korntner, Lehner, Kunkel, Traweger, Trost, Strohmaier, Bogner, Runge, Bruckner, Krefft, Heindl, Reitsamer, Schrödl: Presence of lymphatics in a rat tendon lesion model. in Histochemistry and cell biology 2015
Rare inherited and de novo variants in 2,871 congenital heart disease probands identified GDF1 (show GDF1 Antibodies), MYH6 (show MYH6 Antibodies), and FLT4 as causative genes.
Data show that VEGF-C (show VEGFC Antibodies), VEGF-D (show Figf Antibodies), and VEGFR-3 were expressed in a substantial percentage of breast carcinomas.
There was a significant decrease in VEGFR3 expression in pulmonary arterial endothelial cells from pulmonary arterial hypertension patients.
By treating LECs with VEGF (show VEGFA Antibodies)-C156S and analyzing subsequent changes in gene expression, we identified several 'immediate early (show JUN Antibodies)' transcription factors that showed a rapid transient upregulation VEGFR-3 stimulation. these results reveal an important and unanticipated role of HOXD10 (show HOXD10 Antibodies) in the regulation of VEGFR-3 signaling in lymphatic endothelial cells, and in the control of lymphangiogenesis and permeability.
The normalized methylation values for the VEGFR1 (show FLT1 Antibodies), VEGFR2 (show KDR Antibodies) and VEGFR3 promoters tended to be higher in the tumour cell lines than in normal tonsil samples, whereas amounts of VEGFR1 (show FLT1 Antibodies), VEGFR2 (show KDR Antibodies) and VEGFR3 messenger RNA were significantly higher
These results indicate that VEGF-C (show VEGFC Antibodies)-induced MSC (show MSC Antibodies) osteogenesis is mediated through VEGFR2 (show KDR Antibodies) and VEGFR3, and followed the activation of the ERK (show EPHB2 Antibodies)/RUNX2 (show RUNX2 Antibodies) signaling pathway.
Assessment of VEGFR-2/VEGFR (show KDR Antibodies)-3 on tumor samples might serve as a putative prognostic factor in renal cell carcinoma (show MOK Antibodies) cases, identifying a subset of patients that may benefit from antiangiogenic treatments targeting VEGFR (show KDR Antibodies) receptors.
This study suggests that NRP1 (show NELL1 Antibodies) expression and LVD are independent factors that are likely to predict the risk of LN metastasis in squamous cell carcinoma (SCC (show CYP11A1 Antibodies))of the tongue, whereas the expression of VEGFC (show VEGFC Antibodies), VEGFR3, CCR7 (show CCR7 Antibodies), and SEMA3E (show SEMA3E Antibodies) are nonindependent predictive factors
Data indicate that vascular endothelial growth factor D (VEGF-D (show Figf Antibodies)) was the best indicator of metastasis and vascular endothelial growth factors and receptor-3 (VEGFR-3) may help to determine the prognosis and management of colorectal cancer (CRC (show CALR Antibodies)).
The summarizes the structure and function features of pathway-related molecules of VEGFC (show VEGFC Antibodies)/D-VEGFR3/NRP2 (show NELL2 Antibodies) axis, stages of various tumors and their molecular mechanisms and significances in tuthe expression changes of these molecules in different anatomic organs or histopathologic types or development lymphatic metastasis.
Report the generation of a Vegfr3-CreER (T2) knockin mouse by gene targeting in embryonic stem cells. This mouse expresses the tamoxifen-inducible CreER(T2) recombinase (show RAG1 Antibodies) under the endogenous transcriptional control of the Vegfr3 gene without altering its physiological expression or regulation in the lymphatic system.
Lymphangiogenic growth in the diaphragm was highly dependent on vascular endothelial growth factor receptor (show RYK Antibodies) (VEGFR)-3 signaling. During diaphragm development, macrophages appeared first in a linearly arranged pattern, followed by ingrowth of lymphatic vessels along these patterned lines.
CLEC14A (show CLEC14A Antibodies) acts in vascular homeostasis by fine-tuning VEGFR-2 (show KDR Antibodies) and VEGFR-3 signaling in endothelial cells
VEGFR3 limits VEGFR2 (show KDR Antibodies) expression and VEGF (show VEGFA Antibodies)/VEGFR2 (show KDR Antibodies) pathway activity in quiescent and angiogenic blood vascular endothelial cells, thereby preventing excessive vascular permeability.
Blockade of FLT4 suppresses metastasis of melanoma cells by impaired lymphatic vessels.
Vegf-d (show Figf Antibodies) and its receptor Vegfr-3 were more highly expressed in lungs of hyperoxic, versus normoxic, wild-type mice, indicating that components of the Vegf-d (show Figf Antibodies) signalling pathway are up-regulated in hyperoxia.
this study uncovers a unique molecular mechanism of lymphangiogenesis in which galectin-8 (show LGALS8 Antibodies)-dependent crosstalk among VEGF-C (show VEGFC Antibodies), podoplanin (show PDPN Antibodies) and integrin pathways plays a key role.
Tnfsf15 (show TNFSF15 Antibodies), a cytokine produced largely by endothelial cells, facilitates lymphangiogenesis by up-regulating Vegfr3 gene expression in LECs, contributing to the maintenance of the homeostasis of the circulatory system.
Results showed that the VEGF-C (show VEGFC Antibodies)/VEGFR-3 system underlies the protective effect of ischemic preconditioning against forebrain ischemia in the mouse hippocampus
Experiments in mice and zebrafish demonstrate that changing levels of VEGFR3/Flt4 modulates aortic lumen diameter consistent with flow-dependent remodeling
miR (show MYLIP Antibodies)-126a directs lymphatic endothelial cell sprouting and extension by interacting with Cxcl12a-mediated chemokine (show CCL1 Antibodies) signaling and Vegfc (show VEGFC Antibodies)-Flt4 signal axis.
Ca(2 (show CA2 Antibodies)+) oscillations depended upon VEGF receptor-2 (Vegfr2) and Vegfr3 in endothelial cells budding from the dorsal aorta (DA) and posterior cardinal (show CARD8 Antibodies) vein, respectively.
In the embryo, phenotypes driven by increased Vegfc (show VEGFC Antibodies) are suppressed in the absence of Ccbe1 (show CCBE1 Antibodies), and Vegfc (show VEGFC Antibodies)-driven sprouting is enhanced by local Ccbe1 (show CCBE1 Antibodies) overexpression. Moreover, Vegfc (show VEGFC Antibodies)- and Vegfr3-dependent Erk (show MAPK1 Antibodies) signaling is impaired in the absence of Ccbe1 (show CCBE1 Antibodies).
Flt4 plays an essential role in lymphangiogenesis [review]
The parallel growth of motoneuron axons with the dorsal aorta depends on Vegfc (show VEGFC Antibodies)/Vegfr3 signaling in zebrafish.
Rspo1-Wnt-VegfC-Vegfr3 signaling plays a crucial role as an endothelial-autonomous permissive cue for developmental angiogenesis.
flt4 signalling is suppressed by Dll4 (show DLL4 Antibodies) in developing zebrafish intersegmental arteries.
This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA.
, fms-like tyrosine kinase 4
, soluble VEGFR3 variant 1
, soluble VEGFR3 variant 2
, soluble VEGFR3 variant 3
, tyrosine-protein kinase receptor FLT4
, vascular endothelial growth factor receptor 3
, chylous ascites
, receptor protein tyrosine kinase
, vascular endothelial growth factor receptor-3
, FMS-like tyrosine kinase 4
, tyrosine kinase VEGFR-3
, receptor tyrosine kinase Flt4